[go: up one dir, main page]

WO2018074880A3 - Pharmaceutical composition for preventing or treating pneumonia including quinolin-4-one derivative or pharmaceutically acceptable salt thereof as active ingredient - Google Patents

Pharmaceutical composition for preventing or treating pneumonia including quinolin-4-one derivative or pharmaceutically acceptable salt thereof as active ingredient Download PDF

Info

Publication number
WO2018074880A3
WO2018074880A3 PCT/KR2017/011637 KR2017011637W WO2018074880A3 WO 2018074880 A3 WO2018074880 A3 WO 2018074880A3 KR 2017011637 W KR2017011637 W KR 2017011637W WO 2018074880 A3 WO2018074880 A3 WO 2018074880A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
derivative
preventing
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/011637
Other languages
French (fr)
Korean (ko)
Other versions
WO2018074880A2 (en
Inventor
박철민
송종환
이선경
장수진
김형준
셤데이비드
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Chemical Technology KRICT
Institut Pasteur Korea
Original Assignee
Korea Research Institute of Chemical Technology KRICT
Institut Pasteur Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170097574A external-priority patent/KR101891315B1/en
Priority claimed from KR1020170097569A external-priority patent/KR101915550B1/en
Application filed by Korea Research Institute of Chemical Technology KRICT, Institut Pasteur Korea filed Critical Korea Research Institute of Chemical Technology KRICT
Publication of WO2018074880A2 publication Critical patent/WO2018074880A2/en
Publication of WO2018074880A3 publication Critical patent/WO2018074880A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a quinolin-4-one derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition for preventing or treating pneumonia, wherein the pharmaceutical composition includes the quinolin-4-one derivative or pharmaceutically acceptable salt thereof as an active ingredient. The quinolin-4-one derivative according to the present invention has excellent antibacterial activity, and in particular, unlike conventional antibacterial agents that are typically used, has excellent antibacterial activity against pneumococcus having drug resistance, and thus can be usefully used as a pharmaceutical composition for preventing or treating pneumonia caused by such pneumococcus.
PCT/KR2017/011637 2016-10-20 2017-10-20 Pharmaceutical composition for preventing or treating pneumonia including quinolin-4-one derivative or pharmaceutically acceptable salt thereof as active ingredient Ceased WO2018074880A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR10-2016-0136393 2016-10-20
KR20160136393 2016-10-20
KR1020170097574A KR101891315B1 (en) 2017-08-01 2017-08-01 Pharmaceutical composition for prevention or treatment of pneumonia comprising quinolin 4-one derivative or pharmacurically acceptable salt thereof as an active ingredient
KR10-2017-0097569 2017-08-01
KR10-2017-0097574 2017-08-01
KR1020170097569A KR101915550B1 (en) 2016-10-20 2017-08-01 Pharmaceutical composition for prevention or treatment of pneumonia comprising quinolin 4-one derivative or pharmacurically acceptable salt thereof as an active ingredient

Publications (2)

Publication Number Publication Date
WO2018074880A2 WO2018074880A2 (en) 2018-04-26
WO2018074880A3 true WO2018074880A3 (en) 2018-08-09

Family

ID=62018844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/011637 Ceased WO2018074880A2 (en) 2016-10-20 2017-10-20 Pharmaceutical composition for preventing or treating pneumonia including quinolin-4-one derivative or pharmaceutically acceptable salt thereof as active ingredient

Country Status (1)

Country Link
WO (1) WO2018074880A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3863633A4 (en) 2018-10-09 2022-10-26 Duke University COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS
KR20220074300A (en) 2020-11-27 2022-06-03 재단법인 한국파스퇴르연구소 Antimicrobial composition against Staphylococcus aureus or Enterococcus faecium

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198716A1 (en) * 2001-02-05 2004-10-07 Dorit Arad Cysteine protease inhimbitors
KR20050110237A (en) * 2004-05-18 2005-11-23 한국화학연구원 Fungicidal composition for agriculture and horticulture having a 4-quinolinone derivative
KR20080077889A (en) * 2007-02-21 2008-08-26 (주)바이오버드 Pharmaceutical anticancer composition
US20100190745A1 (en) * 2008-06-04 2010-07-29 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
JP2011173929A (en) * 2003-02-10 2011-09-08 Bayer Schering Pharma Ag Treatment of respiratory bacterial disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198716A1 (en) * 2001-02-05 2004-10-07 Dorit Arad Cysteine protease inhimbitors
JP2011173929A (en) * 2003-02-10 2011-09-08 Bayer Schering Pharma Ag Treatment of respiratory bacterial disease
KR20050110237A (en) * 2004-05-18 2005-11-23 한국화학연구원 Fungicidal composition for agriculture and horticulture having a 4-quinolinone derivative
KR20080077889A (en) * 2007-02-21 2008-08-26 (주)바이오버드 Pharmaceutical anticancer composition
US20100190745A1 (en) * 2008-06-04 2010-07-29 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof

Also Published As

Publication number Publication date
WO2018074880A2 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
WO2016064082A3 (en) Novel aminoalkyl benzothiazepine derivative and use thereof
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
ZA201906451B (en) 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
WO2016126085A3 (en) Heterocyclic compound and pharmaceutical composition comprising same
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
MX2020012989A (en) Therapeutic agent for fibrosis.
EP3694331A4 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
WO2017029602A3 (en) Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system
WO2016112875A3 (en) Diphenyl derivative and uses thereof
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
WO2017079403A3 (en) Polymeric nanoparticles
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2017188720A3 (en) Quinazoline derivative or its salt and pharmaceutical composition comprising the same
WO2018088813A3 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
WO2018074880A3 (en) Pharmaceutical composition for preventing or treating pneumonia including quinolin-4-one derivative or pharmaceutically acceptable salt thereof as active ingredient
WO2017158616A8 (en) Carbapenem compounds
MX2019001771A (en) Solid pharmaceutical composition comprising amorphous sofosbuvir.
WO2016163818A3 (en) Pharmaceutical composition for preventing or treating arthritis or inflammatory disease containing 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17862555

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17862555

Country of ref document: EP

Kind code of ref document: A2